You are here: Industry Insights > ARDS

News List

Novartis terminates remestemcel-L development agreement with Mesoblast Pharmaceutical-Technology
December 16, 2021
Novartis has cancelled an agreement to develop, produce and market Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L.
Stem cell therapy shows promise in COVID-19 respiratory distress europeanpharmaceuticalreview
May 26, 2021
JadiCell™ was shown to significantly improve survival in COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) and also reduce lung scarring associated with long-COVID-19.
Sorrento gets Brazilian ANVISA’s clearance for Phase II Covid-19 trial pharmaceutical-technology
May 24, 2021
Sorrento Therapeutics has received clearance from the Brazilian regulatory agency ANVISA to conduct a Phase II clinical trial of an injectable infusion of mesenchymal stem cells, COVI-MSC, to treat Covid-19 patients with acute respiratory distress ...
Veru initiates enrolment in Phase III trial of sabizabulin for Covid-19 pharmaceutical-technology
May 20, 2021
Veru has enrolled the first subject in Phase III clinical trial of sabizabulin to treat hospitalised Covid-19 patients who are at high risk for acute respiratory distress syndrome (ARDS).
Mesoblast’s remestemcel-L lowers mortality in Covid-19 ARDS patients pharmaceutical-technology
May 06, 2021
Mesoblast has reported that results from a trial showed remestemcel-L reduced mortality in ventilator-dependent Covid-19 patients aged below 65 years with moderate/severe acute respiratory distress syndrome (ARDS) through day 60 by 46%.
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS prnasia
March 29, 2021
Foresee Pharmaceuticals Co., Ltd., today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with ...
Longeveron Expands Enrollment Criteria for Trial Evaluating Lomecel-B Infusion ARDS due to COVID-19 americanpharmaceuticalreview
March 11, 2021
Longeveron announced enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome (ARDS) RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS. Previously, only ARDS patients intubated with ...
Cerecor’s antibody reduces respiratory failure in Covid-19 ARDS trial pharmaceutical-technology
March 03, 2021
Cerecor has reported that final efficacy data from Phase II trial of human anti-LIGHT (TNFSF14) monoclonal antibody, CERC-002, in hospitalised patients with Covid-19 linked pneumonia and mild-to-moderate acute respiratory distress syndrome (ARDS) met ...
Veru reports positive data from Phase II Covid-19 drug trial pharmaceutical-technology
February 10, 2021
Veru has reported positive efficacy and safety results from Phase II clinical trial of an oral drug, VERU-111, in hospitalised Covid-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS).
Desidustat prevents development of ARDS in Phase II COVID-19 trial europeanpharmaceuticalreview
January 28, 2021
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).

Previous page 1 2 3 4 5 6 7 Next page